[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cingulate Inc WT (CINGW)

Cingulate Inc WT (CINGW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

KANSAS CITY, Kan., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to...

CING : 5.09 (+2.00%)
CINGW : 0.0072 (-19.10%)
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile

KANSAS CITY, Kan., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation pharmaceutical products through its proprietary Precision Timed...

CING : 5.09 (+2.00%)
CINGW : 0.0072 (-19.10%)
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology

KANSAS CITY, Kan., July 30, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology...

CING : 5.09 (+2.00%)
CINGW : 0.0072 (-19.10%)
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®

KANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology...

CING : 5.09 (+2.00%)
CINGW : 0.0072 (-19.10%)
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology...

CING : 5.09 (+2.00%)
CINGW : 0.0072 (-19.10%)
Cingulate Receives Complete Response Letter from FDA for CTx-1301

No Clinical Safety or Efficacy Concerns Currently Identified  Agency Feedback Primarily Focused on CMC-Related Requests Company Plans Prompt Response and Submission of Requested Information Company...

CING : 5.09 (+2.00%)
CINGW : 0.0072 (-19.10%)
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

KANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to...

CING : 5.09 (+2.00%)
CINGW : 0.0072 (-19.10%)
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

KANSAS CITY, Kan., March 18, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to...

CING : 5.09 (+2.00%)
CINGW : 0.0072 (-19.10%)
Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

KANSAS CITY, Kan., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced...

CING : 5.09 (+2.00%)
CINGW : 0.0072 (-19.10%)
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Industry Veteran Bryan Downey Named Chief Commercial Officer  NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate...

CING : 5.09 (+2.00%)
CINGW : 0.0072 (-19.10%)

Barchart Exclusives

TurboTax Maker Intuit Leads 3 Cheap, Dividend-Paying Tech Stocks With Up to 151% Upside
Intuit is one of three cheap, dividend-paying tech stocks flying under the radar, with Wall Street price targets suggesting up to 151% upside for the software giant. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.